172732-68-2

Basic information

• Product Name: VARESPLADIB
• Synonyms: VARESPLADIB;LY315920(Varespladib);[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid;LY315920;LY-333013;Varespladib (LY315920);2-[[3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]Acetic Acid;2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yloxy)acetic acid
• CAS NO: 172732-68-2
• Molecular Formula: C21H20N2O5
• Molecular Weight: 380.398
• EINECS: 1592732-453-0
• Product Categories: Inhibitor;Inhibitors
• Mol File: 172732-68-2.mol
• Article Data: 15

Chemical Properties

• Melting Point: 230-234 °C
• Boiling Point: 667.9°C at 760 mmHg
• Flash Point: 357.7°C
• Appearance: /
• Density: 1.32±0.1 g/cm3(Predicted)
• Vapor Pressure: 9.53E-19mmHg at 25°C
• Storage Temp.: -20°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 3.12±0.40(Predicted)
• CAS DataBase Reference: VARESPLADIB(CAS DataBase Reference)
• NIST Chemistry Reference: VARESPLADIB(172732-68-2)
• EPA Substance Registry System: VARESPLADIB(172732-68-2)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 172732-68-2(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 172732-68-2 differently. You can refer to the following data:
1. VARESPLADIB is used as a PLA2 inhibitor (Phospholipase A2 Enzyme inhibitor).
2. Varespladib has been used as a secretory phospholipase A (sPLA2) inhibitor: to test its effect on the human astrocytes subjected to psychosine-induced toxicityto test its neutralization functionality on the black snake species P. colletti?venom in combination with snake venom metalloproteinases (SVMP)-inhibitor, marimastat to test its protective functionality on envenoming by vipers

Biological Activity

phospholipases (plas) produce rate-limiting precursors in the various types of biologically active lipid biosynthesis. increased levels of human nonpancreatic secretory phospholipase a2 (hnps-pla2) have been detected in several pathological conditions. ly315920 was selected for evaluation clinically as an hnps-pla2 inhibitor.

Biochem/physiol Actions

Varespladib is effective against viper and elapid venoms and is used in snakebite therapy. It is reported to interact with the hydrophobic channel of the PLA2-like toxin in in vitro structural studies. It blocks inflammatory cascades related to the sPLA2.

in vitro

the true potency of ly315920 was defined to be a mole fraction of 1.5 x 10-6 using a deoxycholate/phosphatidylcholine assay. ly315920 was found to be 40-fold less active against human, group ib, pancreatic spla2 and was inactive against cytosolic pla2 and the constitutive and inducible forms of cyclooxygenase. human spla2-induced thromboxane a2 release from isolated guinea pig lung bronchoalveolar lavage cells was inhibited by ly315920 with the ic50 of 0.79 μm [1].

in vivo

the i.v. administration of ly315920, 5 min before the bronchoalveolar lavage cells harvest, led to the inhibition of spla2-induced production of txa2 with an ed50 of 16.1 mg/kg. [2].

IC 50

9 ± 1 nm or 7.3 x 10-6 mole fraction for spla2 activity

references

[1] snyder dw, bach nj, dillard rd, draheim se, carlson dg, fox n, roehm nw, armstrong ct, chang ch, hartley lw, johnson lm, roman cr, smith ac, song m, fleisch jh. pharmacology of ly315920/s-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1h-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase a2 inhibitor: a new class of anti-inflammatory drugs, spi. j pharmacol exp ther. 1999;288(3):1117-24.[2] rosenson rs, hislop c, elliott m, stasiv y, goulder m, waters d. effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. j am coll cardiol. 2010;56(14):1079-88.

InChI:InChI=1/C21H20N2O5.Na/c1-2-14-19(20(26)21(22)27)18-15(9-6-10-16(18)28-12-17(24)25)23(14)11-13-7-4-3-5-8-13;/h3-10H,2,11-12H2,1H3,(H2,22,27)(H,24,25);/q;+1/p-1

Upstream product

• 2845-89-8 1-chloro-3-methoxy-benzene 
• 20289-26-3 4-benzyloxy-1H-indole 
• 948553-63-7 (1-Benzyl-3-chlorooxalyl-2-ethyl-1H-indol-4-yloxy)-acetic acid methyl ester 
• 172733-07-2 2-[[2-Ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester 
• 79315-62-1 4-(benzyloxy)-1-(phenylsulfonyl)-1H-indole 
• 2380-94-1 1H-indol-4-ol 
• 889675-05-2 1-(4-(benzyloxy)-1-(phenylsulfonyl)-1H-indol-2-yl)ethanone 
• 889675-07-4 1-benzyl-4-(benzyloxy)-2-ethyl-1H-indole 
• 889675-06-3 1-(4-(benzyloxy)-1H-indol-2-yl)ethanol 
• 39843-70-4 4-(benzyloxy)-2-ethyl-1H-indole 
• 164082-80-8 1-benzyl-2-ethyl-4-methoxy-1H-indole 
• 172733-06-1 1-benzyl-2-ethyl-1H-indol-4-ol 
• 159390-33-7 3-chlorophenyl N,N-diethylcarbamate 
• 791642-67-6 1-chloro-2-iodo-3-methoxybenzene 

Relevant articles and documents

Regioselective synthesis of 4- and 7-alkoxyindoles from 2,3-dihalophenols: Application to the preparation of indole inhibitors of phospholipase A 2

(Chemical Equation Presented) An efficient and regioselective synthesis of 4- and 7-alkoxyindoles has been developed from commercially available starting materials such as 3-halophenols and 3-chloroanisole. Directed ortho-metalation followed by two pallad

Method for treating sepsis

A novel method of treating and/or preventing sepsis.

Method for the treatment of renal dysfunction with spla2 inhibitors

A method is disclosed for the treatment of of the symptoms associated with renal dysfunction by administering to an animal in need thereof a therapeutically effective amount of a sPLA2 inhibitor, such as a 1H-indole-3-glyoxylamide.